83 FR 32301 - Advisory Committee; Science Advisory Board to the National Center for Toxicological Research; Renewal

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Federal Register Volume 83, Issue 134 (July 12, 2018)

The Food and Drug Administration (FDA) is announcing the renewal of the Science Advisory Board (the Board) to the National Center for Toxicological Research (NCTR) by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Board to the NCTR for an additional 2 years beyond the charter expiration date. The new charter will be in effect until June 2, 2020.

[Federal Register Volume 83, Number 134 (Thursday, July 12, 2018)]
[Notices]
[Page 32301]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-14943]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2018-N-2642]


Advisory Committee; Science Advisory Board to the National Center 
for Toxicological Research; Renewal

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; renewal of advisory committee.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the 
renewal of the Science Advisory Board (the Board) to the National 
Center for Toxicological Research (NCTR) by the Commissioner of Food 
and Drugs (the Commissioner). The Commissioner has determined that it 
is in the public interest to renew the Board to the NCTR for an 
additional 2 years beyond the charter expiration date. The new charter 
will be in effect until June 2, 2020.

DATES: Authority for the Board to the NCTR expired on June 2, 2018; 
however, the Commissioner formally determined that renewal is in the 
public interest.

FOR FURTHER INFORMATION CONTACT: Donna L. Mendrick, National Center for 
Toxicological Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 32, Rm. 2208, Silver Spring, MD 20993-0002, 301-
796-8892, [email protected].

SUPPLEMENTARY INFORMATION: Pursuant to 41 CFR 102-3.65 and approval by 
the Department of Health and Human Services pursuant to 45 CFR part 11 
and by the General Services Administration, FDA is announcing the 
renewal of the Board to the NCTR. The Board is a discretionary Federal 
advisory committee established to provide advice to the Commissioner. 
The Board to the NCTR advises the Commissioner or designee in 
discharging responsibilities as they relate to helping to ensure safe 
and effective drugs for human use and, as required, any other product 
for which FDA has regulatory responsibility. The Board advises the NCTR 
Director in establishing, implementing, and evaluating the research 
programs that assist the Commissioner in fulfilling regulatory 
responsibilities. The Board provides an extra-agency review in ensuring 
that the research programs at NCTR are scientifically sound and 
pertinent.
    The Board shall consist of a core of nine voting members including 
the Chair. Members and the Chair are selected by the Commissioner or 
designee from among authorities knowledgeable in the fields of 
toxicological research. Members will be invited to serve for 
overlapping terms of up to 4 years. Almost all non-Federal members of 
this Board serve as Special Government Employees. The core of voting 
members may include one technically qualified member, selected by the 
Commissioner or designee, who is identified with consumer interests and 
is recommended by either a consortium of consumer-oriented 
organizations or other interested persons.
    Further information regarding the most recent charter and other 
information can be found at https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/ToxicologicalResearch/ucm148166.htm or by 
contacting the Designated Federal Officer (see FOR FURTHER INFORMATION 
CONTACT). In light of the fact that no change has been made to the 
committee name or description of duties, no amendment will be made to 
21 CFR 14.100.
    This document is issued under the Federal Advisory Committee Act (5 
U.S.C. app.). For general information related to FDA advisory 
committees, please check https://www.fda.gov/AdvisoryCommittees/default.htm.

    Dated: July 9, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018-14943 Filed 7-11-18; 8:45 am]
 BILLING CODE 4164-01-P